Aerosolized antibiotics for treating hospital-acquired and ventilator-associated pneumonia

Expert Review of Anti-Infective Therapy

Volumn 9, Issue 11, 2011, Pages 993-1000

  Wood, G Christopher ^a  

^a UNIVERSITY OF TENNESSEE COLLEGE OF PHARMACY   (United States)

Author keywords

aerosolization; aerosolized antibiotics; aminoglycosides; colistin; drug delivery; hospital acquired pneumonia; multidrug resistance; nebulization; ventilator associated pneumonia

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIBIOTIC AGENT; CARBENICILLIN; CEFOTAXIME; CEFTAZIDIME; COLISTIN; DOXYCYCLINE; GENTAMICIN; PLACEBO; POLYMYXIN B; RIFAMPICIN; SALBUTAMOL; SISOMICIN; TICARCILLIN; TOBRAMYCIN;

AEROSOL; ALLERGIC PNEUMONITIS; BRONCHOSPASM; CHRONIC LUNG DISEASE; COUGHING; DIZZINESS; DRUG ADMINISTRATION ROUTE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ERADICATION THERAPY; FIBROSIS; HOSPITAL ACQUIRED PNEUMONIA; HUMAN; INFECTION CONTROL; MULTIDRUG RESISTANCE; NEBULIZATION; NEPHROTOXICITY; NONHUMAN; OUTCOME ASSESSMENT; PROCESS OPTIMIZATION; REVIEW; TREATMENT DURATION; VENTILATOR ASSOCIATED PNEUMONIA;

ADMINISTRATION, INHALATION; AEROSOLS; AMINOGLYCOSIDES; ANTI-BACTERIAL AGENTS; COLISTIN; CROSS INFECTION; DRUG ADMINISTRATION SCHEDULE; DRUG DOSAGE CALCULATIONS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; HUMANS; INTENSIVE CARE UNITS; LUNG; NEBULIZERS AND VAPORIZERS; PNEUMONIA, VENTILATOR-ASSOCIATED; PSEUDOMONAS AERUGINOSA; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 80155142495     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/eri.11.126     Document Type: Review

References (39)

1. American Thoracic Society/Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am. J. Respir. Crit. Care 171(4), 388-416 (2005).
2. Aarts MAW, Hancock JN, Heyland D, McLeod RS, Marshall JC. Empiric antibiotic therapy for suspected ventilator-associated pneumonia: a systematic review and meta-analysis of randomized trials. Crit. Care Med. 36(1), 108-117 (2008).
3. Kiem S, Schentag JJ. Interpretation of antibiotic concentration ratios measured in epithelial lining fluid. Antimicrob. Agents Chemother. 52(1), 24-36 (2008).
4. Boucher BA, Wood GC, Swanson JM. Pharmacokinetic changes in critical illness. Crit. Care Clin. 22(2), 255-271 (2006).
5. Pines A, Raafat H, Plucinski K. Gentamicin and colistin in chronic purulent bronchial infections. Br. Med. J. 27(2), 543-545 (1967).
6. Pines A, Raafat H, Siddiqui GM et al. Treatment of severe Pseudomonas infections of the bronchi. Br. Med. J. 14(1), 663-665 (1970).
7. Klastersky J, Geuning C, Mouawad E et al. Endotracheal gentamicin in bronchial infections in patients with tracheostomy. Chest 61(2), 117-120 (1972).
8. Klastersky J, Carpentier Meunier F, Kahan Coppens L et al. Endotracheally administered antibiotics for Gram negative bronchopneumonia. Chest 75(5), 586-591 (1979).
9. Sorensen VJ, Horst HM, Obeid FN et al. Endotracheal aminoglycosides in Gram negative pneumonia: a preliminary report. Am. Surgeon 52(7), 391-394 (1986).
10. Stillwell PC, Kearns GL, Jacobs RF. Endotracheal tobramycin in Gram-negative pneumonitis. Drug Intell. Clin. Pharm. 22(7-8), 577-581 (1988).
11. McCall CY, Spruill WJ, Wade WE. The use of aerosolized tobramycin in the treatment of a resistant pseudomonal pneumonitis. Ther. Drug Monit. 11(6), 692-695 (1989).
12. Hallal A, Cohn SM, Namias N et al. Aerosolized tobramycin in the treatment of ventilator-associated pneumonia: a pilot study. Surg. Infect. (Larchmt) 8(1), 73-82 (2007).
13. Mohr AM, Sifri ZC, Horng HS et al. Use of aerosolized aminoglycosides in the treatment of Gram-negative ventilator-associated pneumonia. Surg. Infect. (Larchmt) 8(3), 349-357 (2008).
14. Czosnowski QA, Wood GC, Magnotti LJ et al. Adjunctive aerosolized antibiotics for treatment of ventilator-associated pneumonia. Pharmacotherapy 29(9), 1054-1060 (2009).
15. Ghannam DE, Rodriguez GH, Raad II, Safdar A. Inhaled aminoglycosides in cancer patients with ventilator-associated Gram-negative bacterial pneumonia: safety and feasibility in the era of escalating drug resistance. Eur. J. Clin. Microbiol. Infect. Dis. 28, 253-259 (2009).
16. Hamer DH. Treatment of nosocomial pneumonia and tracheobronchitis caused by multidruγ-resistant Pseudomonas aeruginosa with aerosolized colistin. Am. J. Respir. Crit. Care Med. 162(1), 328-330 (2000).
17. Motaouakkil S, Charra B, Hachimi A et al. Colistin and rifampicin in the treatment of nosocomial infections from multiresistant Acinetobacter baumannii. J. Infect. 53(4), 274-278 (2006).
18. Sobieszczyk ME, Furuya EY, Hay CM et al. Combination therapy with polymyxin B for the treatment of multidruγ-resistant Gram-negative respiratory tract infections. J. Antimicrob. Chemother. 54(2), 566-569 (2004).
19. Michalopoulos A, Kasiakou SK, Mastora Z et al. Aerosolized colistin for the treatment of nosocomial pneumonia due to multidruγ-resistant Gram-negative bacteria in patients without cystic fibrosis. Crit. Care 9(1), R53-R59 (2005).
20. Kwa ALH, Loh CS, Low JGH et al. Nebulized colistin in the treatment of pneumonia due to multidruγ-resistant Acinetobacter baumannii and Pseudomonas aeruginosa. Clin. Infect. Dis. 41(5), 754-757 (2005).
21. Michalopoulos A, Fotakis D, Virtzili S et al. Aerosolized colistin as adjunctie treatment of ventilator-associated pneumonia due to multidruγ-resistant Gram-negative bacteria: a prospective study. Respir. Med. 102(3), 407-412 (2008).
22. Lin CC, Liu TC, Kuo CF, Liu CP, Lee CM. Aerosolized colistin for the treatment of multidruγ-resistant Acinetobacter baumannii pneumonia: experiences in a tertiary care hospital in northern Taiwan. J. Microbiol. Immunol. Infect. 43(4), 323-331 (2010).
23. Pereira GH, Muller PR, Levin AS. Salvage treatment of pneumonia and initial treatment of tracheobronchitis caused by multidruγ-resistant Gram-negative bacilli with inhaled polymyxin B. Diag. Microbiol. Infect. Dis. 58, 235-240 (2007).
24. Kofteridis DP, Alexopoulou C, Valachis A et al. Aerosolized plus intravenous colistin versus intravenous colistin alone for the treatment of ventilator-associated pneumonia: a matched case-control study. Clin. Infect. Dis. 51(11), 1238-1244 (2010).
25. Horianopoulou M, Lambropoulos S, Papafragas E et al. Effect of aerosolized colistin on multidruγ-resistant Pseudomonas aeruginosa in bronchial secretions of patients without cystic fibrosis. J. Chemother. 17(5), 536-538 (2005).
26. Berlana D, Llop JM, Fort E et al. Use of colistin in the treatment of multiple-drug resistant Gram-negative infections. Am. J. Health-Syst. Pharm. 62(1), 39-47 (2005).
27. Wood GC, Underwood EL, Croce MA, Swanson JM, Fabian TC. Treatment of recurrent Stenotrophomonas maltophilia ventilator-associated pneumonia with doxycycline and aerosolized colistin. Ann. Pharmacother. 44(10), 1665-1668 (2010).
28. Stoutenbeek CP, van Saene HKF, Miranda DR et al. Nosocomial Gram negative pneumonia in critically ill patients: a 3 year experience with a novel therapeutic regimen. Intensive Care Med. 12(6), 419-423 (1986).
29. Wood GC, Swanson JM. Aerosolized antibacterials for the prevention and treatment of hospital-acquired pneumonia. Drugs 67(6), 903-914 (2007).
30. MacIntyre NR, Silver RM, Miller CW et al. Aerosol delivery in intubated, mechanically ventilated patients. Crit. Care Med. 13(2), 81-84 (1985).
31. Miller DD, Amin MM, Palmer LB et al. Aerosol delivery and modern mechanical ventilation: in vitro/in vivo evaluation. Am. J. Respir. Crit. Care Med. 168(10), 1205-1209 (2003).
32. Wood GC, Boucher BA. Aerosolized antimicrobial therapy in acutely ill patients. Pharmacotherapy 20(2), 166-181 (2000).
33. Wood GC, Boucher BA, Croce MA et al. Aerosolized ceftazidime for the prevention of ventilator-associated pneumonia and its effects on the inflammatory response in critically ill trauma patients. Pharmacotherapy 22(8), 972-982 (2002).
34. Claridge JA, Edwards NM, Swanson JM, Fabian TC, Wood GC, Croce MA. Aerosolized ceftazidime prophylaxis against ventilator-associated pneumonia in high risk trauma patients: the results of a double-blinded randomized study. Surg. Infect. (Larchmt) 8(1), 83-90 (2007).
35. Hakeam HA, Almohaizeie AM. Hypotension following treatment with aerosolized colistin in a patient with multidruγ-resistant Pseudomonas aeruginosa. Ann. Pharmcother. 40(9), 1677-1680 (2006).
36. Leong KW, Ong S, Chee HL, Lee W, Kwa AL. Hypersensitivity pneumonitis due to high-dose colistin aerosol therapy. Int. J. Infect. Dis. 14(11), 1018-1019 (2010).
37. Burdette SD, Limkemann AJ, Slaughter JB, Beam WB, Markert RJ. Serum concentrations of aerosolized tobramycin in medical, surgical, and trauma patients. Antimicrob. Agents Chemother. 53(10), 4568 (2009).
38. Le J, Ashley ED, Newhauser MM et al. Consensus summary of aerosolized antimicrobial agents: application of guideline criteria. Pharmacotherapy 30(6), 562-584 (2010).
39. Luyt CE, Clavel M, Guntupalli K et al. Pharmacokinetics and lung delivery of PDDS-aerosolized amikacin (NKTR-061) in intubated and mechanically ventilated patients with nosocomial pneumonia. Crit. Care 13(6), R200 (2009).